ストックスクリーナーアプリを入手
21.23
0.23%
-0.14
前日終値:
$21.37
開ける：
$21.78
24時間の取引高:
209.11K
Relative Volume:
0.64
時価総額：
$1.04B
収益：
-
当期純損益:
$-85.21M
株価収益率:
-11.23
EPS:
-1.89
ネットキャッシュフロー:
$-68.53M
1週間 パフォーマンス:
+19.98%
1か月 パフォーマンス:
+8.28%
6か月 パフォーマンス:
-16.13%
1年 パフォーマンス:
+5.54%
1日の値動き範囲:
$20.99
$22.52
1週間の範囲:
$17.77
$22.64
52週間の値動き範囲:
$13.30
$30.03
Enliven Therapeutics Inc Stock (ELVN) Company Profile
ELVN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
21.23 | 870.49M | 0 | -85.21M | -68.53M | -1.89 |
|
ONC
Beone Medicines Ltd Adr
|
256.90 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.30 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2213 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.27 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
497.50 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-13 | 開始されました | BTIG Research | Buy |
| 2024-09-09 | 開始されました | H.C. Wainwright | Buy |
| 2024-06-11 | 開始されました | Robert W. Baird | Outperform |
| 2024-04-09 | 開始されました | Mizuho | Buy |
| 2023-03-29 | 開始されました | Jefferies | Buy |
Enliven Therapeutics Inc (ELVN) 最新ニュース
Millennium Management LLC Buys 26,449 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Ameriprise Financial Inc. Invests $789,000 in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
What is Lifesci Capital’s Forecast for ELVN FY2025 Earnings? - Defense World
(ELVN) Technical Pivots with Risk Controls - news.stocktradersdaily.com
BNP Paribas Financial Markets Purchases New Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
What is Lifesci Capital’s Forecast for ELVN Q2 Earnings? - Defense World
Enliven Therapeutics (ELVN) Gets a Buy from Mizuho Securities - The Globe and Mail
Mizuho Adjusts Price Target on Enliven Therapeutics to $41 From $39, Maintains Outperform Rating - marketscreener.com
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stake Increased by Deutsche Bank AG - Defense World
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $37.25 Consensus PT from Analysts - Defense World
Enliven Therapeutics to Present at Upcoming Investor Conferences - Nasdaq
(ELVN) Proactive Strategies - news.stocktradersdaily.com
Enliven Therapeutics chief scientific officer sells $81,533 in stock - Investing.com Australia
Enliven Therapeutics chief scientific officer sells $81,533 in stock By Investing.com - Investing.com India
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Purchased by Northern Trust Corp - Defense World
HC Wainwright Issues Pessimistic Outlook for ELVN Earnings - Defense World
Jones Trading Has Lowered Expectations for Enliven Therapeutics (NASDAQ:ELVN) Stock Price - Defense World
Q1 Earnings Forecast for ELVN Issued By HC Wainwright - Defense World
HC Wainwright Raises Enliven Therapeutics (NASDAQ:ELVN) Price Target to $40.00 - Defense World
Jones Trading Lowers Price Target for Enliven Therapeutics (ELVN) | ELVN Stock News - GuruFocus
Enliven (ELVN) Stock Target Cut Amid Mixed Market Reaction | ELVN Stock News - GuruFocus
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Holdings Lifted by Price T Rowe Associates Inc. MD - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 7.6% Following Weak Earnings - Defense World
Enliven Therapeutics Reports Q1 Results and Pipeline Progress - TipRanks
Enliven Therapeutics stock target raised to $40 at H.C. Wainwright By Investing.com - Investing.com South Africa
Enliven Therapeutics: Cash runway can fund ops through late 2027 - BizWest
Enliven Therapeutics (ELVN) Target Price Raised by HC Wainwright & Co. | ELVN Stock News - GuruFocus
Enliven Therapeutics stock target raised to $40 at H.C. Wainwright - Investing.com Australia
H.C. Wainwright Increases Price Target for Enliven (ELVN) Post Q - GuruFocus
H.C. Wainwright Increases Price Target for Enliven (ELVN) Post Q1 Report | ELVN Stock News - GuruFocus
Enliven reports positive Phase 1 trial data for ELVN-001 in CML - Investing.com Nigeria
Tower Research Capital LLC TRC Boosts Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update - PR Newswire
Enliven reports positive Phase 1 trial data for ELVN-001 in CML By Investing.com - Investing.com South Africa
Enliven Therapeutics Says ELVN-001 Shows Favorable Safety And Tolerability Profile - marketscreener.com
Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress - The Malaysian Reserve
Enliven (ELVN) Reports Positive Results from ENABLE Trial for Chronic Myeloid Leukemia | ELVN Stock News - GuruFocus
Breakthrough CML Drug ELVN-001 Achieves 44% Response Rate in Heavily Pretreated PatientsKey Data Revealed - Stock Titan
(ELVN) Investment Analysis - news.stocktradersdaily.com
Enliven Therapeutics (ELVN) Expected to Announce Earnings on Tuesday - Defense World
Wells Fargo & Company MN Has $375,000 Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Invesco Ltd. Buys 508 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Barclays PLC Has $1.45 Million Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Sets New 52-Week Low on Insider Selling - Defense World
JPMorgan Chase & Co. Trims Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven (ELVN) Gains Attention as EHA Data Release Approaches | - GuruFocus
Trading (ELVN) With Integrated Risk Controls - news.stocktradersdaily.com
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stake Lowered by Legal & General Group Plc - Defense World
Enliven Therapeutics chief scientific officer sells $80,365 in stock By Investing.com - Investing.com India
Enliven Therapeutics chief scientific officer sells $80,365 in stock - Investing.com Australia
Enliven Therapeutics Inc (ELVN) 財務データ
収益
当期純利益
現金流量
EPS
Enliven Therapeutics Inc (ELVN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Kintz Samuel | PRESIDENT AND CEO |
Jun 03 '25 |
Sale |
20.05 |
7,500 |
150,352 |
965,392 |
1.30%
3.35%
大文字化:
|
ボリューム (24 時間):